# To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

> **NCT01300208** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 48 (actual)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** CC-11050
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01300208
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2013-01-01
- **Final completion:** 2013-03-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300208, "To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01300208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*